Trial Profile
A Phase 2 Study of E7777 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma and Cutaneous T-cell Lymphoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Dec 2021
Price :
$35
*
At a glance
- Drugs Denileukin diftitox (Primary)
- Indications Anaplastic large cell lymphoma; Cutaneous T-cell lymphoma; Extranodal NK-T-cell lymphoma; Mycosis fungoides; Peripheral T-cell lymphoma; Sezary syndrome; T-cell lymphoma
- Focus Therapeutic Use
- Sponsors Eisai Co Ltd
- 01 Jun 2021 Results evaluating efficacy, safety, pharmacokinetics, and immunogenicity of E7777 in Japanese patients with relapsed/refractory peripheral and cutaneous T-cell lymphoma, published in the Cancer Science
- 23 Mar 2021 According to an Eisai media release, based on the data from this study, the company has obtained manufacturing and marketing approval for the Remitoro for Intravenous Drip Infusion 300 ug (denileukin diftitox) with relapsed or refractory Peripheral T-cell Lymphoma (PTCL) and relapsed or refractory Cutaneous T-cell Lymphoma (CTCL), in Japan.
- 26 Mar 2020 According to an Eisai media release, based on the data from this study, company has submitted in Japan a marketing authorization application of the anticancer agent denileukin diftitox for relapsed or refractory Cutaneous T-cell Lymphoma (CTCL) and Peripheral T-cell Lymphoma (PTCL).